Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults

Participants needed: Adult organ transplant recipients

Purpose

This study will evaluate an investigational mRNA vaccine against RSV in immunocompromised adults aged 18 and older, including people who have received a kidney, liver, and/or lung transplant(s).

The study vaccine, mRNA-1345, is being studied to see if it will prevent RSV.

About RSV

RSV, or Respiratory Syncytial Virus, is a common cause of respiratory tract infection, which involves the passage formed by the mouth, nose, throat, and lungs. Most people have been infected at least once by the time they are 2 years old. It remains the leading cause of untreated severe lower respiratory tract disease (infection of the lungs) and hospitalizations in infants and young children worldwide and a significant cause of lung infections in older adults.

Older adults (aged 60 years and older) with any other illness such as heart and lung diseases are at a greater risk of having a serious outcome if they become infected.

Eligibility

To take part in this study, you must be:

• 18 years or older
• Had a solid organ transplant ≥180 days prior to day of consent, receiving chronic immunosuppressive therapy for the prevention of allograft rejection
• Have not received the RSV vaccine before

Eligible participants are primarily informed of this study by a healthcare provider. If you believe you may be eligible and would like more information, contact ccfv@iwk.nshealth.ca.